|By PR Newswire||
|August 6, 2014 03:00 PM EDT||
Input will help shape the role of public contributions to orphan drug approvals
OTTAWA, Aug. 6, 2014 /CNW/ - The Honourable Rona Ambrose, Minister of Health, announced today that the Government of Canada has launched a pilot project targeting patient input from Canadians with rare diseases to help inform future reviews of orphan drugs. As announced in October of 2012, Health Canada has been developing an Orphan Drug Framework to spur innovation and research into new treatments for rare diseases and also to encourage patient participation. The Pilot Project will simulate how input from patients will be gathered and incorporated into the drug submission review process once the Orphan Drug Framework is in effect.
Drug manufacturers, Hoffmann-La Roche Limited and Hyperion Therapeutics, Inc have agreed to participate in the pilot with two of their drug review submissions. The review of Hoffmann-La Roche's medication obinutuzumab for the treatment of chronic lymphocytic leukemia (CLL) will be used for the pilot. Hyperion Therapeutics Inc.'s review is for Ravicti ® (glycerol phenylbutyrate) Oral Liquid which is used for the treatment of urea cycle disorders. Hoffmann-La Roche and Hyperion's participation will serve as models for how patient input may inform drug authorization decisions.
Patients will be asked to comment on the following:
- how the rare disease affects their ability to manage their day-to-day lives;
- what treatments are currently available (if any);
- what therapeutic benefits are most important to them; and
- their risk tolerance for any new treatments.
Health Canada will be asking patient advocacy groups including the Canadian Organization for Rare Disorders to assist in engaging specific Canadian patients affected by CLL or urea cycle disorders to participate in the project. The patient feedback provided during the pilot will assist Health Canada in assessing and refining its approach to gathering patient input. This will ensure that patient perspectives are considered in future orphan drug authorizations.
- Orphan drugs are those drugs used to treat rare diseases. A rare disease is a life-threatening, seriously debilitating, or serious chronic condition that only affects a very small number of patients (typically less than 5 in 10,000 persons).
- When the Orphan Drug Framework is fully implemented, Canadian patients will be invited to participate in future orphan drug authorizations through Health Canada's website.
Patients with CLL or urea cycle disorders, their current or former caregivers or healthcare professionals, and others with first-hand knowledge of CLL or urea cycle disorders are encouraged to contact Health Canada by email if they wish to participate at: [email protected].
"No one has a better understanding of what it means to have a rare
disease than the patients who are affected by them. The input of these
patient volunteers is absolutely invaluable and our government has
committed to making their experiences and perspectives an important
addition to our scientific approach to drug assessments for rare
Minister of Health
"Roche recognizes that patients and patient organizations are playing an
increasingly important role in drug review and health technology
assessment and bring valuable experience, perspective and insight to
the process. As an organization committed to patients, Roche is pleased
to participate in this Health Canada pilot program that is seeking
patient input within the regulatory review process."
Vice President, Medical & Regulatory Affairs, Hoffmann-La Roche Limited
"As part of our full commitment to serving the urea cycle disorder
community, we're looking forward to participating in Health Canada's
Patient Involvement Pilot Project. Orphan diseases have a dramatic
impact on the lives they touch, making this initiative critical to the
process of drug review and approval."
Dr. Bruce Scharschmidt
Senior Vice president, Chief Medical and Development Officer, Hyperion Therapeutics, Inc.
"Kudos to Health Canada for recognizing the value of the direct patient
voice in the drug review process, for designing a user-friendly
template that will encourage patient engagement, and for piloting this
in advance of the orphan drug regulations. The Canadian Organization
for Rare Disorders is pleased to have had the opportunity to
collaborate on this important initiative and to promote this in the
President, Canadian Organization for Rare Disorders
SOURCE Health Canada
There is an ever-growing explosion of new devices that are connected to the Internet using “cloud” solutions. This rapid growth is creating a massive new demand for efficient access to data. And it’s not just about connecting to that data anymore. This new demand is bringing new issues and challenges and it is important for companies to scale for the coming growth. And with that scaling comes the need for greater security, gathering and data analysis, storage, connectivity and, of course, the...
May. 4, 2016 12:15 AM EDT Reads: 1,105
Much of the value of DevOps comes from a (renewed) focus on measurement, sharing, and continuous feedback loops. In increasingly complex DevOps workflows and environments, and especially in larger, regulated, or more crystallized organizations, these core concepts become even more critical. In his session at @DevOpsSummit at 18th Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, will show how, by focusing on 'metrics that matter,' you can provide objective, transparent, and meaningfu...
May. 3, 2016 11:45 PM EDT Reads: 991
Many private cloud projects were built to deliver self-service access to development and test resources. While those clouds delivered faster access to resources, they lacked visibility, control and security needed for production deployments. In their session at 18th Cloud Expo, Steve Anderson, Product Manager at BMC Software, and Rick Lefort, Principal Technical Marketing Consultant at BMC Software, will discuss how a cloud designed for production operations not only helps accelerate developer...
May. 3, 2016 11:30 PM EDT Reads: 1,231
Artificial Intelligence has the potential to massively disrupt IoT. In his session at 18th Cloud Expo, AJ Abdallat, CEO of Beyond AI, will discuss what the five main drivers are in Artificial Intelligence that could shape the future of the Internet of Things. AJ Abdallat is CEO of Beyond AI. He has over 20 years of management experience in the fields of artificial intelligence, sensors, instruments, devices and software for telecommunications, life sciences, environmental monitoring, process...
May. 3, 2016 11:00 PM EDT Reads: 1,197
Manufacturers are embracing the Industrial Internet the same way consumers are leveraging Fitbits – to improve overall health and wellness. Both can provide consistent measurement, visibility, and suggest performance improvements customized to help reach goals. Fitbit users can view real-time data and make adjustments to increase their activity. In his session at @ThingsExpo, Mark Bernardo Professional Services Leader, Americas, at GE Digital, will discuss how leveraging the Industrial Interne...
May. 3, 2016 11:00 PM EDT Reads: 1,264
The IoTs will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, will demonstrate how to move beyond today's coding paradigm and share the must-have mindsets for removing complexity from the development proc...
May. 3, 2016 10:45 PM EDT Reads: 742
The IETF draft standard for M2M certificates is a security solution specifically designed for the demanding needs of IoT/M2M applications. In his session at @ThingsExpo, Brian Romansky, VP of Strategic Technology at TrustPoint Innovation, will explain how M2M certificates can efficiently enable confidentiality, integrity, and authenticity on highly constrained devices.
May. 3, 2016 10:00 PM EDT Reads: 1,200
Increasing IoT connectivity is forcing enterprises to find elegant solutions to organize and visualize all incoming data from these connected devices with re-configurable dashboard widgets to effectively allow rapid decision-making for everything from immediate actions in tactical situations to strategic analysis and reporting. In his session at 18th Cloud Expo, Shikhir Singh, Senior Developer Relations Manager at Sencha, will discuss how to create HTML5 dashboards that interact with IoT devic...
May. 3, 2016 10:00 PM EDT Reads: 1,310
We're entering the post-smartphone era, where wearable gadgets from watches and fitness bands to glasses and health aids will power the next technological revolution. With mass adoption of wearable devices comes a new data ecosystem that must be protected. Wearables open new pathways that facilitate the tracking, sharing and storing of consumers’ personal health, location and daily activity data. Consumers have some idea of the data these devices capture, but most don’t realize how revealing and...
May. 3, 2016 09:45 PM EDT Reads: 309
SYS-CON Events announced today that Ericsson has been named “Gold Sponsor” of SYS-CON's @ThingsExpo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. Ericsson is a world leader in the rapidly changing environment of communications technology – providing equipment, software and services to enable transformation through mobility. Some 40 percent of global mobile traffic runs through networks we have supplied. More than 1 billion subscribers around the world re...
May. 3, 2016 08:45 PM EDT Reads: 1,270
In the world of DevOps there are ‘known good practices’ – aka ‘patterns’ – and ‘known bad practices’ – aka ‘anti-patterns.' Many of these patterns and anti-patterns have been developed from real world experience, especially by the early adopters of DevOps theory; but many are more feasible in theory than in practice, especially for more recent entrants to the DevOps scene. In this power panel at @DevOpsSummit at 18th Cloud Expo, moderated by DevOps Conference Chair Andi Mann, panelists will dis...
May. 3, 2016 08:45 PM EDT Reads: 949
We’ve worked with dozens of early adopters across numerous industries and will debunk common misperceptions, which starts with understanding that many of the connected products we’ll use over the next 5 years are already products, they’re just not yet connected. With an IoT product, time-in-market provides much more essential feedback than ever before. Innovation comes from what you do with the data that the connected product provides in order to enhance the customer experience and optimize busi...
May. 3, 2016 08:30 PM EDT Reads: 1,193
The increasing popularity of the Internet of Things necessitates that our physical and cognitive relationship with wearable technology will change rapidly in the near future. This advent means logging has become a thing of the past. Before, it was on us to track our own data, but now that data is automatically available. What does this mean for mHealth and the "connected" body? In her session at @ThingsExpo, Lisa Calkins, CEO and co-founder of Amadeus Consulting, will discuss the impact of wea...
May. 3, 2016 08:00 PM EDT Reads: 1,033
If there is anything we have learned by now, is that every business paves their own unique path for releasing software- every pipeline, implementation and practices are a bit different, and DevOps comes in all shapes and sizes. Software delivery practices are often comprised of set of several complementing (or even competing) methodologies – such as leveraging Agile, DevOps and even a mix of ITIL, to create the combination that’s most suitable for your organization and that maximize your busines...
May. 3, 2016 07:30 PM EDT Reads: 1,914